ETP-ALL is characterized by an active hematopoietic stem cell renewal program and high expression of LYL1, LMO2, MEF2C, HHEX, and BCL2 (1, 5, 25, 26). This evidence concerns the gene MEF2C and acute lymphoblastic leukemia.